Drug
AS1411
AS1411 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
unknown1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
unknown125%
completed250%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
NCT01034410
completedphase_2
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
NCT00512083
unknownphase_2
A Phase II Study of AS1411 in Renal Cell Carcinoma
NCT00740441
completedphase_1
Study of AS1411 in Advanced Solid Tumours
NCT00881244
Clinical Trials (4)
Showing 4 of 4 trials
NCT01034410Phase 2
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
NCT00512083Phase 2
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
NCT00740441Phase 2
A Phase II Study of AS1411 in Renal Cell Carcinoma
NCT00881244Phase 1
Study of AS1411 in Advanced Solid Tumours
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4